EnteroBiotix

EnteroBiotix is a clinical-stage biopharmaceutical company developing orally delivered, full-spectrum microbiome therapeutics for diseases linked to gut microbiome disruption.

Its lead asset EBX-102-02 demonstrated clinically meaningful improvements in irritable bowel syndrome in Phase 2a trials, with a Phase 2b study planned for 2026.

The company operates MHRA-licensed GMP manufacturing facilities in Glasgow, uses proprietary drying technology, and manages its donor supply chain through its platform.

Additional programmes target liver cirrhosis and immuno-oncology indications.